JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate

Karuna Therapeutics is 24 months out from a hotly anticipated schizophrenia drug launch, and the industry is buzzing with rumors that the biotech will seek a Big Pharma partnership or other deal for commercialization.